The Researcher OG

01/05/2026

Cannabinoids help calm inflammation by acting through the ECS, our Master Regulator, which influences immune signaling throughout the body. When inflammation spikes, immune cells release cytokines, chemical messengers that act like alarm signals. In metabolic, autoimmune, and chronic inflammatory conditions, those alarms can stay stuck in the “on” position, exhausting the system and preventing immune peace from returning.

Cannabinoids such as CBG, CBD, and others have been shown to lower pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, reducing the intensity of the inflammatory alarm, creating the biological space for regulatory T cells (Tregs) to form and function more effectively.

A 2020 study titled Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome via Induction of Regulatory T Cells demonstrated that CBD reduced inflammatory cytokines and increased Treg populations in a lung injury model, suggesting that cannabinoids can shift immune tone away from hyperinflammation toward regulation. Tregs are immune cells that act like referees, telling other immune cells when to stop attacking, calm down, and rebuild tolerance. The 2020 study showed that when cytokine signaling was reduced, the immune environment favored the induction of FoxP3+ Tregs, the most well-known marker of functional Tregs.

Another study, titled Cannabigerol Suppresses Inflammatory Responses and Promotes Regulatory T Cell Differentiation, 2024, explored CBG’s ability to reduce inflammatory cytokines and promote Treg differentiation, highlighting its role in immune balance rather than immune suppression. Tregs develop when inflammation is sufficiently dialed down for the immune system to shift from emergency to repair mode. Cannabinoids do not directly “create” Tregs by force, they reduce the cytokine pressure that blocks Treg development, allowing the immune system to transition naturally into a self-regulating state where tolerance is rebuilt, and inflammatory chaos slows.

The mechanism is multi-layered: cannabinoids influence CB2 receptors on immune cells, reduce NF-κB signaling, lower pro-inflammatory cytokines, and raise anti-inflammatory mediators, a combination that supports Treg differentiation and stability. Chemical reduction of cytokines removes the roadblocks, Treg biology restores the rules of engagement, and the immune system regains its ability to regulate itself rather than burn itself out in perpetual alarm. That pattern is why cannabinoids are being studied for autoimmune disease, metabolic inflammation, and immune dysregulation, not as blunt immunosuppressants, but as modulators that support the Master Regulator’s ability to restore equilibrium.

Every immune system needs brakes, not just gas pedals. Cannabinoids help the body find those brakes by calming the alarms long enough for Tregs to step onto the field and do their job. That is the science of immune tone resetting through the ECS, and it always leads back to one key principle: ECS Balance.

-Mike Robinson, The Researcher OG

01/05/2026

Recent research shows that cannabigerol (CBG) holds real promise as a tool for addressing metabolic syndrome through its effects on the ECS, our Master Regulator. A key study titled Cannabigerol Attenuates Diet-Induced Obesity and Metabolic Dysregulation in Mice, 2023 explored how CBG influenced weight gain, lipid profiles, insulin sensitivity, and inflammatory markers in an established metabolic syndrome model. This work is an important step in understanding how cannabinoids beyond THC and CBD can influence whole-body regulation.

In the 2023 study, researchers gave CBG to mice on a high-fat diet and observed improvements in multiple metabolic endpoints compared with controls. The treated group showed reduced adiposity, better glucose tolerance, and lower circulating triglycerides compared with untreated counterparts. What made this work compelling was how CBG appeared to act through multiple pathways that link back to the ECS, our Master Regulator, including modulation of lipid metabolism and inflammatory tone.

The ECS plays a central role in energy balance, glucose regulation, and immune communication. When ECS tone becomes imbalanced, it contributes to insulin resistance, chronic inflammation, and pathological fat accumulation, classic hallmarks of metabolic syndrome. CBG’s interactions with ECS receptors and enzymes appear to support balance restoration, helping the body respond more effectively to metabolic stressors.

This research also noted that CBG influenced markers of hepatic steatosis, suggesting liver benefits in the context of overnutrition. That aligns with what clinicians are seeing in early translational work, where adjusting endocannabinoid activity correlates with improvements in fatty liver markers and systemic metabolic health. The multi-target nature of CBG contrasts with that of single-pathway pharmaceuticals, which gently nudge the ECS and related signaling networks toward equilibrium.

For consumers and patients navigating metabolic challenges, these findings signal a broader cannabinoid horizon where support for balance goes beyond symptom suppression to addressing underlying regulatory control. CBG’s promise in metabolic syndrome ties back to its role in fine-tuning the Master Regulator rather than forcing change through blunt receptor activation.

The science isn’t finished, but study after study confirms cannabinoids like CBG deserve serious attention for metabolic regulation through the ECS. When support is balanced, the system responds with restored tone, clearer glucose handling, and reduced systemic stress. This is the future of cannabinoid-informed metabolic care rooted in regulation and balance.

-Mike Robinson, The Researcher OG

01/05/2026

The 1940s were a pivotal decade in cannabis chemistry, not because every molecule was fully defined, but because resin was finally separated into meaningful chemical families. Labs were working with solvent extraction, acidic fractions, phenols, and neutral compounds, documenting behavior long before naming conventions or modern analytical tools existed. This era laid the foundation for everything that followed.

In 1940, Roger Adams, Hunt, and Clark published the first well-documented isolation of cannabidiol in the Journal of the American Chemical Society. That single milestone shifted plant-chemistry research forward, proving cannabinoids could be purified and studied structurally, even if many compounds remained chemically inferred rather than explicitly named.

Throughout the 40s, Adams’ team repeatedly referenced “red oil” and acidic resin fractions. These extracts almost certainly contained precursor molecules to oxidized rearranged acids like those later classified into the cannabielsoin acid family. At the time, they lacked the resolution to characterize oxidative rearrangement acids at the molecular level, but their chemical behavior was observed and documented, awaiting better tools to translate the details.

Cannabielsoins like CBE and CBEA are oxidative rearrangement acids that form when phenolic precursors such as CBDA undergo oxidation-driven structural shifts. These metabolites and acids were formally classifiable only after HPLC, NMR, and mass spectrometry matured enough to confirm their structures, decades later. This is a common theme in natural-product chemistry: isolate first, name later, define fully once the science catches up.

This historical pattern matters for patients and consumers today because it reminds us that the plant communicates through systems, not isolated endpoints. Cannabinoids, especially in their raw, acidic, and oxidative forms, influence receptor signaling and lipid tone through the ECS, our Master Regulator. When supported properly, receptors regain sensitivity, enzymatic tone stabilizes, and system balance becomes achievable.

The 40s opened the resin, later decades assigned names, and modern science validated structure, but the target has always been the same: restoring tone, sensitivity, and regulation through the Master Regulator. Understanding this timeline helps us respect both the history and the science, without overstating what the 1940s could measure at the time.

Plant medicine research keeps advancing, cannabinoid chemistry keeps evolving, but the core principle stays steady. ECS Balance remains the key to response, regulation, and restored sensitivity over time.

-Mike Robinson, The Researcher OG

01/05/2026

Join Montel Williams on this episode of Let's Be Blunt with Montel as he welcomes Mike Robinson, founder of the Global Cannabinoid Research Center and CEO of Nanobles Corp.

Mike shares his incredible personal story as a multiple cancer survivor who leveraged cannabis medicine to overcome devastating illnesses, including epilepsy, Lyme disease, and chronic pain.

Explore how Mike’s groundbreaking research is shaping the future of cannabinoid medicine, including innovations like Genevieve’s Dream and the revolutionary PREVENT therapy for cancer care. From restoring balance to the endocannabinoid system to disrupting traditional healthcare approaches, Mike offers unique insights into the limitless potential of cannabis science.

Tune in to discover how his passion for helping patients and advancing endocannabinoid research is transforming lives across the globe.

Join Montel Williams on this episode of Let's Be Blunt with Montel as he welcomes Mike Robinson, founder of the Global Cannabinoid Research Center and CEO of...

01/05/2026

Nobody should accept the death sentence doctors can give us - I'm still here today when i was given one way back then. A year before I met my girls I relapsed with Non Hodgkin's once again, and was facing the 2 stage 4 cancers I already had and that at Stage 4 again as bone metastasis was in multiple places with lymph nodes affected globally. I walked away from Cancer Treatment figuring I'd die and continued to give away Oils. And then I met my girls... and lived.

01/04/2026

How clean is your concentrate? If you are choosing extracts from dabs to v**e pens, it is vital to understand what you are actually inhaling. Cannabis extracts can be powerful medicine or potent irritants, depending on how they are made and what impurities they contain. Potency alone does not equal purity, and that distinction matters more than most consumers realize.

Concentrates come in many forms: solvent-based, like butane or ethanol extractions, and solventless, like rosin made with heat and pressure. Solvent-based methods can produce very high cannabinoid content, but if the process is not carefully controlled, leftover solvents and breakdown products can remain in the extract. Those remnants can irritate the lungs and respiratory tissues and interact poorly with the nervous system.

Solventless rosin avoids chemical solvents, but it still carries whatever was in the plant itself. If the flower contains pesticides or heavy metals, those contaminants do not disappear during pressing; they become part of the final product.

Distillates and v**e cartridges add another layer of complexity. Distillation can remove components the processor does not want, but it can also concentrate contaminants that were already present. V**e cartridges introduce hardware concerns, including metals and plastics that heat up and volatilize into the aerosol the consumer inhales. Many illness outbreaks linked to illicit va**ng products show that additives and cutting agents can do much more harm than the cannabinoids themselves.

A truly clean concentrate starts with clean cultivation. If the plant was exposed to pesticides, fungicides, heavy metals from soil or water, these chemicals do not get filtered out by extraction. They are pulled right into the extract. Lighting, nutrients, soil microbiome, and water quality all influence the chemical profile of the flower and the extract it produces. Clean input equals cleaner output; that is the biological reality.

Transparency from brands about how products are made and what testing they run matters a great deal. You want to know how the extract was produced, what methods were used, and what steps were taken to avoid contaminants at every stage. Claims of purity without backing do not protect your lungs or your health.

Extracts can be remarkable tools for rapid-onset, targeted relief when made with care and integrity. They can also be sources of irritation and harm when shortcuts are taken in processing or the plant itself is compromised.

Clean means more than strength it means honoring the biology of the system you are asking your body to interact with, and ensuring you are choosing products that reflect that priority. In a still-evolving industry, the consumer role remains education, vigilance, and asking questions that matter for health and performance.

-Mike Robinson, The Researcher OG

01/04/2026

For athletes, the conversation around recovery isn’t fringe; it’s fundamental. Training stress, micro-trauma, inflammation, joint irritation, and nervous system fatigue aren’t side notes; they are signals the body uses to adapt or break down. The ECS, our Master Regulator, sits at the center of that signal network, guiding inflammation, pain perception, sleep rhythm, stress recovery, and metabolic balance. When that system is supported, the athlete can train harder, recover faster, and stay durable under daily load. That’s where CBGa enters the conversation with a unique profile that supports balance without sedation or intoxication.

CBGa is the raw cannabinoid the plant produces before heat alters it. It acts upstream in the biological cascade, influencing key pathways tied to inflammation and immune signaling. Research into CBGa shows it can reduce inflammatory markers by interacting with COX enzymes and modulating immune cell communication, meaning less swelling and calmer tissues after heavy exertion. That is valuable for athletes because persistent inflammation is one of the main obstacles to recovery and performance progression.

Beyond inflammation, CBGa influences receptors linked to nerve sensitivity and mood, including TRP channels involved in pain perception and neural excitability. When those channels are moderated, the nervous system can shift out of chronic protective tension into a state that supports calm recovery and better sleep rhythm. Athletes know that rest is where gains are made, and CBGa supports that transition without blunt sedation or fog.

CBGa also plays a role in metabolic signaling. While the research is still emerging, early evidence suggests that CBGa can influence lipid metabolism and energy balance in ways that support stamina and recovery-fuel utilization. That means an athlete’s system is getting biochemical support where it counts, rather than just managing symptoms.

Importantly, CBGa does not force the system into an off state it supports regulation at the ECS level, so the body can decide what it needs. That means less lingering soreness, more efficient inflammation resolution, and clearer neural signaling that supports focus, coordination, and resilience under physical load. It is not a shortcut; it is a biological ally that works with the Master Regulator to help athletes train, adapt, and recover at the pace their goals demand.

-Mike Robinson, The Researcher OG

01/04/2026

Migraines are not just bad headaches; they are neurologic storms in which inflammation, nerve irritation, and vascular changes activate pain loops that overwhelm the system. The ECS, our Master Regulator, helps control neural excitability, vascular tone, and inflammatory signaling. When that balance slips, migraines hit harder and more often. Cannabinoids like CBGa, CBG, and CBD are showing up in research and patient experience as tools that help the body calm those loops rather than just mask pain.

A key study published in Frontiers in Pharmacology 2020 titled Cannabinoids in Migraine: A Review of the Evidence analyzed clinical and preclinical data on cannabis and cannabinoid effects on migraine pathways. The researchers found that cannabinoids interact with serotonin receptors, TRP channels, and endocannabinoid signaling pathways involved in pain and inflammation, and that plant cannabinoids can reduce migraine frequency and intensity more consistently than a placebo in small clinical settings. Frontiers in Pharmacology 2020 confirms that cannabinoids modulate pain signaling and inflammatory triggers that are core to migraine biology.

CBGa is the plant’s primordial cannabinoid. In early research, CBGa reduces inflammatory markers, such as COX enzymes, and influences serotonin receptor activity before it decarboxylates into other molecules. For migraine pathways, that means upstream inflammatory triggers get dampened, so nerve irritation and vascular responses don’t escalate as sharply. CBGa’s role is subtle, upstream, and focused on reducing the very signals that ignite a migraine attack.

CBG brings a second layer of modulation. It interacts with TRPV1 channels and serotonin systems tied to nerve firing thresholds and pain perception. For many patients, CBG translates into a softer onset of migraine pain and reduced peak intensity by helping the nervous system resist overreaction to common triggers like light, sound, or stress.

CBD supports broader neural stability. It helps slow the breakdown of endocannabinoids like anandamide, supports serotonin signaling, and moderates inflammatory cascades tied to vascular changes and nerve sensitivity. In both clinical feedback and controlled studies, CBD has been associated with fewer migraine days and a reduction in acute severity.

None of these cannabinoids forces sedation or shuts down function. They calm the loops that amplify migraine pain so the nervous system can reset. When consumers and patients integrate CBGa, CBG, and CBD into a mindful migraine plan with hydration, sleep support, and trigger awareness, the result is often fewer attacks, lower pain peaks, and a nervous system that no longer feels at war with itself.

-Mike Robinson, The Researcher OG

01/03/2026

Rheumatoid arthritis (RA) is more than joint pain - it is an immune-driven inflammatory condition where the body attacks its own joint lining, causing swelling, stiffness, and persistent pain. When inflammation stays high, sleep suffers, movement shrinks, and many patients cycle through medications that help some, but rarely reset the core imbalance. This is where the cannabinoid conversation gets interesting, not because of hype, but because of biology.

CBG, CBD, and THC are showing up in patient stories and early clinical observations as meaningful tools for relief. Each works differently, but together they can complement the goal: supporting the ECS, our Master Regulator, toward equilibrium.

CBD acts as an inflammation modulator. It interacts with serotonin receptors linked to mood and pain perception, influences TRPV1 channels involved in tissue irritation, and may slow the breakdown of internal lipids, such as anandamide. For many patients, consistent CBD use has led to reduced stiffness, calmer pain signaling, and improved mobility, especially when paired with hydration and baseline medical care.

CBG brings a quieter, but potent angle. It has shown anti-inflammatory effects in cellular models, influencing pathways tied to immune balance without suppressing immune function entirely. Patients often describe reduced joint swelling, less aggressive flare intensity, and more functional comfort when CBG-rich products are added into their routine.

THC works more directly. It engages CB1 receptors in the brain and immune tissues, softening pain circuits tied to the amygdala, reducing inflammatory feedback loops, and supporting a better sleep rhythm that RA often disrupts. Low-to-moderate THC use for many consumers has meant fewer overnight pain spikes, improved rest, and less morning stiffness waiting at the door.

The collective effect is not about sedation - it is about regulation. Many patients report that combined cannabinoid protocols help them rely less on steroids, carry less NSAID load, and move through daily tasks with less resistance. Every ECS baseline is different, so dosing and timing vary, but the stories carry a common rhythm: less stiffness, more movement, fewer spikes, and more comfort in the body they live in.

The real value isn’t one cannabinoid doing everything - it is synergy, timing awareness, hydration support, and restoring balance at the Master Regulator level. That is how patients with RA are finding relief, reclaiming movement, reclaiming sleep, and steering the system back toward regulatory calm, instead of living in the flare-pain-repeat loop.

-Mike Robinson, The Researcher OG

01/03/2026

Holding CBGa concentrate on top of THC Distillate with terps helps show the world what ECS Balance looks like with cannabinoids. If we’re going to use the ultra-strong natural plant THC, we need to offset that with ingestion of cannabinoids like CBGa and CBDa that help our Endocannabinoid System (ECS) to regain it’s equillibrium. This causes numbed receptors to fire up again, new ones to replace the old, and circulates our bodies' cannabinoids, aka endocannabinoids, throughout our bodies, allowing our own fuel to mix with that of the plants. Now that’s a dynamic duo if I’ve ever heard of one, plant and endocannabinoids working together to calm the storms of life.

CBGa - everyday! Let’s talk more about why you should be using it now.

-Mike Robinson, The Researcher OG

01/03/2026

Raw cannabinoids like THCa, CBGa, and CBDa are the acid forms the plant produces before heat or time converts them into their more famous counterparts. Think of them as the plant’s original blueprints - untouched, unheated, and packed with biological intent.

THCa doesn’t intoxicate until it’s decarboxylated into THC, but in its raw form, it has shown strong anti-inflammatory and neuroprotective potential. One key study, Tetrahydrocannabinolic Acid A (THCA-A) Shows Potent Neuroprotective Activity, 2012, demonstrated that THCA may help protect neurons from oxidative stress, acting through PPAR-gamma pathways and reducing inflammatory damage in neural cells.

CBGa is often called the mother of many cannabinoids because it sits at the top of the plant’s cannabinoid cascade. It has shown promise in controlling inflammation, supporting metabolism, and regulating neuro-lipid signaling. In Cannabigerolic Acid Exhibits Anti-Inflammatory Properties (2021), CBGa reduced inflammatory markers in cell models, demonstrating activity at pathways that influence immune balance without suppressing immune function.

CBDa is a powerhouse inflammation modulator and digestive system influencer. In Cannabidiolic Acid Reduces Inflammation and Pain via TRPA1 Activation, 2018, CBDa demonstrated the ability to reduce inflammatory signaling and pain by activating TRPA1 channels, which are deeply involved in tissue irritation, gut motility, and inflammatory cascades. It also interacts with serotonin receptors in ways that CBD doesn’t always match.

The value here is synergy and signaling intelligence. Raw cannabinoids interact with enzyme systems, lipid networks, and receptors involved in immunity, mood, metabolism, and neural protection, often without the side effects or tolerance pressure seen with heated or synthetic analogs. They help the ECS, our Master Regulator, lean back toward equilibrium, giving the system breathing room to regulate itself rather than forcing exaggerated receptor states.

For consumers and patients exploring cannabinoid support, the raw acids offer clarity without intoxication, and biological compatibility without the chaos of lab novelty molecules. Raw cannabinoids are not weak; they’re strategic - subtle where needed, potent where it counts, and deeply aligned with the Master Regulator’s role in restoring balance.

-Mike Robinson, The Researcher OG

01/03/2026

Sometimes it feels like the world wants to reinvent THC at the lab table like we’re running low on supply - which is wild when you consider the sheer volume of THC already on Planet Earth, doing what it does without needing chemical gymnastics. I don’t favor CBD converted into THC or any synthetic analogs, because those conversions feel ridiculous when nature already produced more than enough THC to study, extract, and educate around.

The real trouble starts when patients and consumers overindulge on cannabinoids they never even knew existed, like THCP, or worse, lab-converted alternatives. The phone calls I’ve taken over that chaos are far more troubling than any conversation about botanical THC could ever be.

The clearest evidence on the dangers of lab-created cannabinoids comes from the peer-reviewed study Toxicity of Synthetic Cannabinoids in K2-Spice 2023. This paper reviewed emergency cases tied to synthetic cannabinoids sold in products like K2 and Spice, confirming higher toxicity risks compared to natural cannabis.

These molecules bind as full CB1 receptor agonists, triggering exaggerated and unpredictable effects that natural THC does not typically produce. Documented outcomes included neurological harm, severe agitation, psychosis, altered consciousness, seizures, cardiovascular strain, kidney injury, respiratory complications, and fatalities. The study makes it clear that synthetic cannabinoids carry serious health risks due to uncontrolled receptor activation, toxicological unpredictability, and dangerous byproducts formed during chemical synthesis. MDPI 2023.

This isn’t fear-mongering - it’s pharmacology meeting real-world data. THC from the plant evolved alongside the ECS, our Master Regulator, shaping receptor interactions over centuries of human use. Lab-created cannabinoids were engineered for novelty and potency, not safety or systemic balance. That potency is exactly where the nightmares begin.

When society prioritizes education, informed THC use, and Master Regulator equilibrium over synthetic novelty, the path ahead becomes safer for patients, consumers, and the entire cannabinoid community. The real solution isn’t new molecules - it’s access, clarity, dosing awareness, hydration, whole-plant synergy, and protecting the balance that biology already built.

-Mike Robinson, The Researcher OG